Intrarenal hemodynamic alterations induced by anti-GBM antibody  by Boyce, Neil W. & Holdsworth, Stephen R.
Kidney International, Vol. 31 (1987), pp. 8—14
LABORATORY INVESTIGATION
Intrarenal hemodynamic alterations induced by anti-GBM
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Intrarenal bemodynamic alterations induced by anti-GBM antibody.
An isolated perfused kidney system (IPK) was used to study the direct
intrarenal hemodynamic effects of binding of anti-glomerular—basement
membrane (anti-GBM) antibody in the absence of all other circulating
humoral and cellular inflammatory mediators. Control IPK's (perfused
with Krebs—Henseleit buffered 5% albumin solution containing non-
immune globulin) had a renal vascular resistance (RVR) mean SEM
3.10 0.47mm Hg/mI/mm and a GFR mean SEM 0.63 0.8 ml/min/g.
Anti-GBM antibody administration raised RVR (4.83 0.52 mm
Hg/mI/mm, P < 0.01) and lowered GFR (0.34 0.04 ml/min/g, P <
0.01). Perfusate renin activity was higher after antibody administration
(684 87 ng AL/mi/hr compared with control 308 42 ngAI/ml/hr, P <
0.01). Treatment with Sar1Ala8All (3 x l0-6M) or captopril (10 mg/mI)
attenuated antibody—induced vasoconstriction (RVR mm Hg/mi/mm,
Sara'Ala8All = 3.78 0.13 captopril = 3.26 0.12, both P < 0.05
compared with anti-GBM alone). Both inhibitors of the renin—angio-
tensin system (RAS) also aggrevated the decline in GFR seen after
antibody administration (GFR ml/min/g, Sara'Ala8All = 0.24 0.05,
Captopril = 0.18 0.03, both P < 0.05 compared with anti-GBM
alone). These IPK studies demonstrate that anti-GBM antibody itself
may directly induce intrarenal hemodynamic alterations in the absence
of complement activation, neutrophil infiltration, neural influences or
circulating vasoactive substances. The results from perfusate renin
sampling and blockade of the RAS provide evidence that anti-GBM
antibody deposition activates the intrarenal RAS and thereby induces
significant hemodynamic alterations.
follow antibody deposition through a variety of potential ef-
fector mechanisms. The potential for complement activation
and inflammatory cell infiltration to produce hemodynamic
change has been demonstrated in experimental GN [10, 11].
However, in a variety of experimental and human nephritides,
inflammatory cells are absent and complement is only sparsely
or inconsistently deposited [14—15], clearly indicating that com-
plement and inflammatory cell independent mechanisms of
injury exist. In whole animal studies it is difficult to discern the
individual contribution of each mediator towards the produc-
tion of renal injury [13]. An IPK system facilitates administra-
tion of single putative mediators in an environment which is
devoid of all other circulating humoral and cellular mediators of
injury. The isolated organ system is also not subject to either
neural or systemic hemodynamic influences. We therefore
chose to use an IPK system to assess the direct effects of
antibody binding on intrarenal hemodynamics. This system
allowed the dissection of the direct effects of antibody itself on
the kidney from indirect effects due to activation of regional and
systemic injury mediation systems.
Methods
Perfusion technique
Anti-GBM antibody—induced glomerulonephritis (antiGBM-
GN) is a widely studied model of immune renal injury [1—4]. The
development of renal injury is typically monitored by assessing
changes in glomerular permeability, using measurements of
urinary protein excretion rates. The important contributions of
hemodynamic alterations to the evolution of both immunologi-
cal and non-immunological renal disease have recently been
emphasized [5—7]. While renal injury in acute glomerulonephri-
tis is acknowledged to involve alterations in renal hemodynam-
ics [7—10], the mechanisms by which immunological stimuli
induce these changes remain incompletely understood [10—13].
In studies of the renal hemodynamic changes occurring in
glomerulonephritis in vivo there are difficulties in dissecting the
relative influences of altered autonomic tone, altered levels of
circulating vasoactive substances, and systemic hemodynamic
changes on intrarenal hemodynamics [13]. Immune injury may
Received for publication July 19, 1985,
and in revised forms February 24 and June 9, 1986
© 1987 by the International Society of Nephrology
8
The perfusion apparatus used in these experiments was
similar to that described by Bowman and Maack [16] and
modified by Nakane et a! [17] and Epstein et al [18]. The
apparatus consisted of a central glass reservoir containing the
perfusate which was recirculated by a roller peristaltic pump
(Watson—Marlow, London, UK). The perfusate traversed two
bubble traps and two 8 filters (Millipore, Bedford, Massachu-
setts, USA) before being gassed with a mixture of 95% 02/5%
CO2 and delivered to the glass arterial perfusion cannula (P.A.
Brooks, Ducklington, UK).
Male Sprague—Dawley (SD) rats (300 to 450 g) were anaes-
thetized with an intraperitoneal injection of pentobarbital (40
mg/kg). A laparotomy was performed after injection of 1 ml of
10% mannitol and 500 IU sodium heparin (Commonwealth
Serum Laboratories, Melbourne, Australia) into the left femoral
vein. The right ureter was cannulated with polyethylene tubing
(PE-lO, Intramedic, Parsippany, New Jersey, USA). The right
renal artery was cannulated via the superior mesenteric artery
and the kidney perfused during en-bloc dissection. After re-
moval the kidney surface was rinsed with phosphate buffered
saline (PBS) and 20 to 40 ml of perfusate flushed through the
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renal vasculature before transferring the kidney to a support
above the central reservoir. The renal vein was not cannulated.
The kidney was allowed to equilibrate for 10 minutes. The
perfusate flow rate was >20 mi/mm at a cannula tip pressure
<120mm Hg by the end of this equilibration period. The kidney
was covered with a paraffin film (Nescoflim, Bando Chemical
md. Ltd., Kobe, Japan) and perfused for periods up to 150
minutes. Samples of perfusate were taken at 10 minute intervals
and urine was collected over 20 minute intervals. All samples
were stored at —20°C prior to assay. Globulin fractions were
added to the perfu sate reservoir at the end of the equilibration
period (t0). After the end of the equilibration period no adjust-
ment to perfusion pressure and/or flow were made in either
experimental or control perfusions.
The IPK perfusate consisted of a buffered albumin solution
(BAS), a Krebs—Henseleit buffer containing 5.0 g/liter bovine
serum albumin (Sigma Chemical Co., St. Louis, Missouri,
USA) with added creatinine 10 to 20 mg/liter), glucose (5
mM/liter) and amino acids [181 was prepared. It was prefiltered
and then passed through a 0.22 s filter (Millipore) before use
within eight hours of preparation. Renin assays were performed
by the Laboratory of Professor Cohn I. Johnston using previ-
ously described methods [19].
Perfusate containing normal sheep globulin (1 mg/ml) or
anti-GBM antibody (1 mg/mI) was assayed for angiotensinogen
activity by substituting perfusate for plasma renin substrate in a
previously described renin assay (assay sensitivity 0.2 ng
Al/mi).
The renin source used in this assay was hog renin (1 unit).
Normal rat plasma incubated under identical conditions in this
assay generates 441.4 14.9 ng AI/ml. Sheep renin substrate
generates 1,109.1 40,5 ng Al/mi. The perfusate did not
interfere with the detection of Al in this assay over the 0.2 to 20
ng/ml range tested. Incubation of perfusate with hog renin (1
unit) resulted in no measured A! generation at 0, 1, 2, 4 and
6 hours. The sensitivity of this assay is 0.2 nglml. The perfusate
thus contained less than 0.05% of the angiotensinogen activity
of normal rat plasma.
Assessment of renal function
Protein excretion. This was measured in duplicate samples by
the Comassie Brilliant Blue dye binding assay [20].
Glomerular filtration rate (GFR). This was measured in
duplicate samples by both the inulin clearance and creatinine
clearance techniques, which gave identical results.
Renal vascular resistance (RVR). Perfusate pressure was
measured proximal to the arterial cannula with a calibrated
anaeroid manometer. The cannula tip pressures were derived
by subtracting from the measured pressure the pressure drop
known to occur across a particular arterial cannula (of known
resistance at a given flow). Perfusate flow was measured by a
drop counter above the central reservoir. Then, resistance =
cannula tip pressure (mm Hg)/perfusate flow (ml/min).
Sodium (Na) and creatinine (Cr) estimates. Sodium was
determined using a flame photometer (Beckman Instruments,
Palo Alto, California, USA). Creatinine was determined using a
colorimetric automated analyser (Beckman). The fractional
reabsorption of sodium (FRNa) was calculated by
FRNa(%)=1 xlOO
GFR.PNa
where UNa = urine Na (mM/liter), V = urine flow (mllmin) and
PNa = perfusate Na (mM/liter).
Renin activity. Perfusate renin activity was determined by
radioimmunoassay for angiotensin I after incubation with rat
plasma renin substrate for 30 and 60 minutes and then ex-
pressed as the amount of angiotensin I formed during one hour
of incubation [19].
Regional perfusate flow. Microspheres were used to assess
the distribution of perfusate flow between outer and inner renal
cortex as previously described [211. Radioactive scandium
(46Sc) and cerium ('41Ce) labelled microspheres of 15 diameter
(New England Nuclear, Boston, Massachusetts, USA) sus-
pended in 10% dextran and 0.1% Tween 80 were prepared for
injection by sonicating for 10 minutes. Ten thousand micro-
spheres suspended in 10 j.tl were mixed with 40 d of perfusate
and injected in to the arterial perfusion cannula. '41Ce-labelled
microspheres were injected during the control period and the
"Sc-labelled microspheres injected 45 minutes after addition of
antibody. The cortex of the middle third of the kidney was
carefully dissected into inner and outer cortex, weighed and
from their respective radioactivities, and regional flow was
determined [211.
Histological assessment
Tissue for immunofluorescence was taken after completion of
perfusion, snap—frozen in liquid nitrogen and stored at —70°C.
Two—micron frozen sections were cut on a cryostat and then
stained with antisera to sheep globulin (IgG, Dakopatts, Swe-
den), Sheep C3 (research Plus Inc., Bayonne, New Jersey,
USA) rat IgG (Sigma), and rat C3 (United States Biochemical
Corporation, Cleveland, Ohio, USA). The sections were exam-
ined under a Leitz Othlux II UV microscope (Leitz, Heerbrugg,
Switzerland).
Antibodies
Normal sheep globulin (NSG). Normal sheep serum was
extensively absorbed against SD rat red blood cells (RB C's) and
plasma. A globulin fraction was obtained by precipitation with
saturated ammonium sulphate. The precipitate was resus-
pended in phosphate buffered saline (PBS) and passed through
a 0.22 s filter.
Sheep-anti-rat GBM globulin (anti-GBM antibody). Sheep
were repeatedly immunized with particulate SD GBM as pre-
viously described [22]. When a high titer of anti-GBM antibody
was established, as determined by radioimmunoassay (RIA) the
sheep was sacrificed. The sera was absorbed and a globulin
fraction prepared as for NSG.
Quantitation of antibody binding. Paired—label globulin bind-
ing studies were performed for every perfusion after trace
radiolabelhing the globulin with NSG or antiGBM-Ab with
'31lodine or 25Iodine using the Chloramine-T technique [23].
Trace labelled globulins were added at the end of the IPK
equilibration period to a known volume of perfusate, and
perfusate was sampled after thorough mixing had occurred for
determination of its specific activity. At the desired time the
kidney was removed from the perfusion apparatus, trimmed of
UNa.V
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Table 1. Control perfused kidneys
..Additions to LPK
perfusate Parameter
Time, mm
20 40 60 80 100 120
Control IPK function
Drug NSG N Protein excret
mg/mm
0,253 .047 0.174 .031 0.155 .028 0.217 .065 0.23 1 .046 0.309 .048
Nil 1 mg/mI 13 GFR mi/mmnlg
RVR mm Hg/mi!
mm
Fractional
reabsorption of
sodium (%)
SEM
0.68 .09
3.23 .40
90 2.4
0.67 .08
2.72 .27
91 1.8
0.63 .06
2.82 .20
90 2.8
0.60 .09
2.83 .30
91 1.8
0.62 .08
3.27 .34
90 2.4
0.57 .08
3.90 .47
90 2.4
Additions to IPK perfusate
Protein excretion
mg/mm
0.198 .115 0.221 .119 0.197 .084 0.183 .104 0.178 .081 0.188 .101Drug NSG N
Captopnl 1 mg/mI 6 GFR mi/min/g
RVR mm Hg/mi!
mm
Protein excretion
mg/mm
0.67 0.06
3.10 .42
0.213 .114
0.69 0.08
2.89 .51
0.225 .097
0.65 0.04
2.70 .49
0.210 .105
0.63 0.05
2.76 .55
0.173 .114
0.61 0.04
2.80 .61
0.185 .099
0.61 0.04
2.82 .47
0.179 .100
Saralasin 1 mg/mI 6 GFR mi/mmn/g
RVR mm Hg/mi!
mm
0.66 0.04
3.15 .51
0.67 0.05
3.01 .45
0.64 0.06
2.78 .35
0.61 0.05
2.80 .42
0.59 0.04
2.81 .39
0.58 0.06
2.96 .41
capsule, excess connective tissue and fat and the renal cortex
dissected free. The cortex was then weighed before being
homogenized in a glass tube homogenizer. The homogenate was
repeatedly washed in 50 ml of PBS until the supernatant was
clear. Specific kidney fixed antibody levels (KFA) were as-
sessed as previously described [23] and expressed as g anti-
body globulin bound per gram of renal cortex (g/g). The
perfusions continued for a maximum of 150 minutes, with
protein excretion, GFR, RVR and FRNa calculated for each 20
minutes interval to quantitate renal function. Control (NSG)
perfusions contained concentrations of globulin equivalent to
the maximal antibody concentrations achieved (1 mg!ml). The
ability of corticosteroids, antihistamines, renin—angiotensin in-
hibitors and prostaglandin synthetase inhibition to modify the
effects of anti-GBM-Ab administration was assessed by perfus-
ing with methylprednisolone (400 mg!ml), promethazine (500
mg/ml) captopril (10 mg/mI), Sara'A1a8A1I (3 x 106M) and
indomethacin (1 mg/mI), added during the equilibration period.
Statistical methods
Data is expressed as mean SEM. Results of GFR and RVR
for sequential 20 minute intervals are shown in the Tables. In
the text all data is presented as the overall mean SEM for the
120 minute study period. Significance values for comparisons
between grouped data were determined using the one—way
analysis of variance.
Results
BAS perfused controls
Isolated rat kidneys, perfused with a buffered albumin solu-
tion with added normal sheep globulin (1 mg/mI) and stable
function for the 120 minutes of the study (Table 1). Urinary
protein excretion ranged from 0.155 to 0.309 mg/mm (mean
0.223 0.44 mg/mm), GFR ranged from 0.57 to 0.68 ml/min/g
(mean 0.63 0.08 ml/min/g), RVR ranged from 2.72 to 3.90 mm
Hg/mi/mm (mean 3.10 0.47 mm Hg/mllmin) and FRNa was>
90%. Perfusate samples assayed from control (N = 6) kidneys
demonstrated a basal renin activity of 308 24 ngAI/ml/hr.
Perfusate containing NSG or antiGBM antibody had no demon-
strable angiotensinogen activity.
Globulin/antibody binding studies
Antibodies bound to the perfused kidney in a dose related
fashion. Anti-GBM-Ab was shown to localize to the GBM with
linear staining on IF, with no significant staining of the vascular
endothelium or renal tubular basement membrane. No other
immune reactants were deposited in glomeruli by IF examina-
tion.
Effects of anti-GBM antibody alone
At KFA 385 agIg. Anti-GBM-Ab binding at this level pro-
duced marked renal hemodynamic change, as indicated by an
increased RVR (4.83 0.52 mm Hg/ml/min, P < 0.01) and a
decreased GFR (0.34 0.04 ml/min/g, P < 0.01) (Table 2, Fig.
1). Renal protein excretion also increased (2.009 0.681
mg/mm, P < 0.01), as discussed in a companion study [24]. This
level of antibody binding increased perfusate renin activity
significantly (684 87 ng/Al/mi/hr P < 0.01) (Fig. 1).
At KFA 183 ag/g & 89 j.ig/g. Antibody binding at these KFA
levels was associated with no change in the rate of protein
excretion, although a fall in GFR (0.41 0.08 ml/min/g) and rise
in RVR (4.72 0.43 mm Hg/mI/mm) still occurred, both of
which were significant (P < 0.05) (Table 2). These hemody-
namic changes were quantitatively similar to those occurring at
the 385 ig/g dose, as was the increase in perfusate renin activity
(595 63 ngAI/ml/hr, P <0.05).
At KFA 89 ag/g. At this level of binding anti-GBM-Ab
produced no discernible alteration in protein excretion (0.222 to
0.003 mg/mi, GFR (0.66 0.04 ml/min/g) or RVR (3.85 1.24
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Table 2. Effects of antibody alone on IPK function
AntiGBM antibody
KFA SEM N
Parameter\time,
mm SEM 20 40 60 80 100 120
385 g/g 16
183 g/g 8
89 jig/g 4
9
6
4
Protein excretion
mg/mm
GFR mI/mmn/g
RVR mm Hg/mI/mm
Protein excretion
mg/mm
GFR mi/minlg
RVR mm Hg/mI/mm
Protein excretion
mg/mm
GFR ml/min/g
RYR mm Hg/mI/mm
0.487
0.49
3.75
0.337
0.51
4.04
0.200
0.69
3.80
.124
.03
.27
.068
.04
.41
.024
.03
1.21
1.058
0.40
4.43
0.237
0.47
3.92
0.200
0.68
3.75
.372
.04
.73
.069
.06
.43
.183
.02
1.17
1.214
0.34
4.20
0.248
0.42
4.91
0.213
0.68
3.68
.380
.04
.56
.064
.05
.69
.106
.02
1.05
1.668
0.27
4.94
0.326
0.41
5.12
0.209
0.65
3.79
.441
.05
.56
.087
.05
.63
.021
.02
1.23
2.502
0.31
5.26
0.316
0.38
5.06
0.236
0.63
3.98
.500
.05
.64
.112
.04
.67
.076
.03
1.61
5.126 1.618
0.23 .04
6.41 .52
0.374 .001
0.28 .04
5.25 .55
0.274 .089
0.64 .02
4.12 1.34
mm HgIml/sec) (Table 2). Perfusate renin activity was not
significantly different from control values (334 35 ngAI/mlI
hr).
Pharmacological studies in IPK's given anti-GBM Ab. In
IPK perfusions performed with the addition of anti-GBM Ab
(385 tg/g) there was no significant amelioration of injury in the
presence of corticosteroids, (prednisolone), antihistamines
(promethazine) or a prostaglandin—synthetase inhibitor (indo-
methacin) (Table 3). However inhibition of the renin—angio-
tensin system using an All receptor antagonist (Sara'A1a8A1I)
and an angiotensin—converting enzyme inhibitor (captopril)
reduced antibody induced vasoconstriction (RVR mm
HgIml/min Sara1AlatAll 3.78 0.13, captopril 3.26 0.12, both
P < 0.05 of antibody alone). This reduction in vasoconstriction
resulted in both a fall in perfusion pressure and a rise in
perfusate flow rates when compared with antibody treated
preparations. RAS inhibition also exaggerated the fall in GFR
produced by antibody (GFR ml/min/g Sara1Ala8All 0.24 0.05,
captopril 0.18 0.03, both P < 0.05 cf antibody alone). The
hemodynamic (that is, GFR and RVR) changes induced by
captopril treatment were more marked than those with saralasin
(P < 0.05). None of the inhibitors significantly altered protein
excretion rates or the quantity of antibody deposited in
glomeruli (Table 3). The administration of captopril or saralasin
to control (NSG) IPK's resulted in no significant alterations in
IPK function (Table 1).
Regional perfusate flow. Control perfusions had 69.7 1.9%
of total cortical perfusate flow directed to the superficial cortex
and 30.3 1.9% to the deep cortex (Fig. 2). Antibody admin-
istration Sara'AlatAll treatment and captopril treatment did not
significantly alter the distribution of cortical perfusate flow as
assessed by microsphere distribution.
Discussion
The isolated perfused rat kidney was initially developed by
Weiss for the study of renal hemodynamics [251. It allows
assessment of the direct effects of agents on renal hemodynam-
ics, eliminating extrarenal influences such as the sympathetic
nervous system, systemic hemodynamic alterations and circu-
lating vasoconstrictor substances [24—26]. The IPK also facili-
tates the study of individual inflammatory mediators by allow-
ing their sequential repletion to the circulating perfusate
[27—29], avoiding many of the difficulties inherent to in-vivo
mediator depletion studies. Finally, the IPK is an ideal system
with which to study renal vasoconstriction [25, 26, 30], as it is
a system in which accurate pressure/flow data is easily ob-
tained, thus facilitating detection and quantitation of increases
in vascular tone.
The current study clearly demonstrates that anti-GBM anti-
body itself can directly induce renal hemodynamic changes.
Furthermore, the IPK model has allowed dissection of the
mechanism of action of antibody induced injury within the
organ of interest. Whole animal studies have suggested that the
hemodynamic changes following anti-GBM antibody adminis-
tration are largely due to glomerular complement activation and
neutrophil infiltration [11, 12]. However in mediator depletion
studies, in vivo antibody induces hemodynamic alterations
despite apparent blockade of the complement system and
prevention of glomerular neutrophil infiltration [12]. In whole
animal studies, many potential circulating substances could
account for the hemodynamic changes induced by antibody
deposition in complement and neutrophil depleted animals. The
IPK allows evaluation of the effects of individual mediators on
intrarenal hemodynamics, and clearly demonstrates that anti-
body can directly induce intrarenal hemodynamic changes in
the absence of any other circulating factors. In the current
study, in the absence of other inflammatory mediator systems
(that is, complement, neutrophils), a relatively high level of
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Fig. 1. The administration of antibody, saralasin and captopril did nor
significantly alter regional cortical perfusare flow from control values.
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Table 3. Attempted blockade of the effects of anti-GBM antibody on IPK function
Drug added to the
IPK perfusate N Parameter
Time, mm
20 40 60 80 100 120
Methyl 6 Protein excretion 0.485 .114 0.815 .164 0.217 .224 1.558 .277 2.095 .299 2.105 .319
prednisolone mg/mm
GFR mi/minlg
RVR mm Hg/mI/mm
0.60 .01
3.74 .33
0.53 .03
3.89 .42
0.47 .03
3.89 .58
0.42 .03
4.08 .61
0.37 .05
4.43 .60
0.34 .06
5.92 .76
Promethazine 4 Protein excretion 0.391 .100 0.6444 .297 0.653 .139 1.220 .320 1.322 .508 1.999 .422
hydrochloride mg/mm
GFR mI/minig
RVR mm Hg/mI/mm
0,49 .05
3.65 .19
0.47 .06
3.64 .36
0.43 .01
4.07 .41
0.39 .02
4.98 .64
0.28 .02
5.61 .78
0.22 .04
5.65 .80
Indomethacin 4 Protein excretion
GFR mllmmnig
RVR mm Hg/mI/mm
0.440 .130
0.56 .08
4.36 .23
0.608 .120
0.51 .11
4.60 .66
0.154 .245
0.47 .13
5.27 .76
1.192 .315
0.42 .14
6.62 .72
1.593 .209
0.40 .12
6.40 .58
2.132 .352
0.37 .12
6.71 .50
Captopril 6 Protein excretion
mg/mm
GFR mi/minlg
RVR mm Hg/mI/mm
0.248 .102
0.41 0.04
3.28 .16
0.458 .183
0.20 0.03
2.78 .32
1.221 .853
0.12 0.05
2.82 .41
1.426 .898
0.15 0.04
2.88 .36
1.985 .735
0.09 0.03
3.25 .45
2.024 .857
0.08 0.03
3.88 .49
Saralasin 6 Protein excretion
mg/mill
GFR mI/minig
RVR mm Hg/mI/mm
0.259 .085
0.45 0.05
3.37 .09
0.685 .342
0.28 0.03
3.24 .10
1.059 .305
0.20 0.02
3.49 .15
1.936 .480
0.20 0.02
3.75 .15
2.304 .887
0.18 0.03
4.20 .13
2.461 .914
0.16 0.02
4.64 .13
The addition of corticosteroid, promethazine or indomethacin to the IPK perfusate did not significantly alter the injury produced by anti-GBM
antibody. Saralasin and captopril both significantly attenuated the hemodynamic injury induced by anti-GBM antibody binding at 380 g 1 g KFA.
bound antibody was required to induce hemodynamic changes.
In vivo, multiple mediator systems contribute to immune renal
injury. The relative importance of antibody itself in immune
renal injury will vary in proportion to the quantity of glomerular
bound immunoglobulin [311.
Antibody—induced hemodynamic abnormalities may be pro-
duced by two alternative mechanisms. Anti-GBM antibody
binding may exert its hemodynamic effects directly by interac-
tion with vascular structures or indirectly by promoting the
release of mediator substances from intrinsic renal parenchymal
cells. The antibody used did not bind to vascular structures,
making it unlikely that direct antigen—antibody interactions
provoked the observed hemodynamic changes. The alternative
mechanism is that of anti-GBM antibody—stimulated local re-
lease of mediator substances. The ability of intrinsic renal cells
to elaborate inflammatory/vasoactive mediators has recently
been demonstrated by Pirotsky et al (29), highlighting the
possible contribution of such mechanisms to the production of
renal injury.
This hypothesis led us to investigate the effects of pretreat-
ment of our IPK preparation with antagonists of several puta-
tive mediators. There was no effect of pretreatment with a
prostaglandin synthetase inhibitor (indomethacin), a histamine
antagonist (phenergan), or corticosteroids (methyl predniso-
lone). However pretreatment with an angiotensin—convert-
ing—enzyme (ACE) inhibitor (captopril) or a competitive antag-
onist of angiotensin II (Sara1AlatAII) markedly attenuated
antibody induced vasoconstriction and augmented the decline
in GFR seen after antibody administration. The changes which
occurred with captopril pretreatment were quantitatively more
pronounced than those with Sara1Ala8AII. This may reflect an
additional modifying effect on the renal vasculature by other
vasoactive substances produced by captopril therapy such as,
bradykinin, prostaglandins [321. Alternatively, it may reflect a
reduced availability of Sara'AIatAII at intrarenal All binding
sites [331.
Perfusate renin activity in control IPK preparations was
similar to previously reported values [33—35], with a significant
increase occurring after antibody administration. The aug-
mented renin release which followed antibody administration is
likely to be a specific consequence of antibody binding to the
glomerular basement membrane, as the hemodynamic changes
per se would be expected to lead to a markedly decreased,
rather than an increased, perfusate renin activity [35]. The
mechanism/s by which antibody binding promotes intrarenal
renin release remain speculative. It is possible that glomerular
immunoglobulin deposition alters the physical environs of the
juxtaglomerular cell (such as, electrostatic charge:GBM confor-
mation) and directly stimulates renin release. Alternatively, the
release of a "second messenger" from intrinsic glomerular cells
could indirectly promote renin release from juxtaglomerular
cells. As there is no source of renin substrate (angiotensinogen)
in the IPK perfusate, the vascular responses following antibody
administration, and their modification by inhibition of the
renin—angiotensin system (RAS), must reflect changes in the
activity of the intrarenal RAS. The importance of the intrarenal
RAS in a variety of physiological and pathophysiological cir-
cumstances is increasingly recognized [32, 37—39]. Previous in
vivo studies have failed to define a role for All mediation of the
hemodynamic alterations in anti-GBM-GN [10]. The current
studies utilized a dose of Sara'AlatAII which was adequate to
inhibit the intrarenal RAS [32]. Previous in vivo studies have
used doses of SaratAla8All which, while sufficient to inhibit the
RAS intravascularly, would be expected to have little effect on
the intrarenal RAS [10, 33], thus a contribution of the intrarenal
RAS to the hemodynamic changes in anti-GBM-GN would have
remained unrecognized. It would be exceedingly difficult to
interpret renal hemodynamic changs occurring in whole animal
studies using large doses of All receptor antagonists or con-
verting enzyme inhibitors, as these agents exert pronounced
effects on systemic hemodynamics, in addition to their effects
on the intrarenal RAS. In the current study neither captopril nor
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Sar&AIa8AII significantly altered the relative distribution of
cortical perfusion following anti-GBM antibody administration
and there was a marked fall in GFR, despite vasodilatation,
after RAS blockade in antibody treated kidneys. These data
suggest that the prime site of action of the antibody—stimulated
increase in intrarenal All was on the efferent arteriole (a finding
consistent with data from other investigators [19, 32—39]), and
that antibody binding reduced the glomerular capillary ultrafil-
tration coefficient (Kf). Thus, while the fall in Kf led to a
reduction in GFR, the activation of the RAS 'protected' GFR
by constriction of the efferent arteriole and elevation of the
mean transcapillary hydraulic pressure difference (P). Block-
ade of the RAS in antibody treated preparations prevented this
'protective' elevation of P, resulting in exacerbation of the
antibody—induced decline in GFR simultaneous with reduction
in total RVR.
As we have reported elsewhere [24] antibody administration
in the IPK is also associated with the development of heavy
proteinuria and loss of the negative charge barrier on the
glomerular filter, The magnitude of the increase in protein
excretion is far in excess of that which could be explained in
terms of hemodynamic changes alone. There are different
antibody binding thresholds for the development of hemody-
namic alterations and for the development of altered glomerular
permselectivity. Furthermore, RAS blockade with restoration
of near—normal perfusate flow does not protect against the
development of proteinuria. In combination these data suggest
that there are independent mechanisms which mediate the
changes in renal hemodynamics and the altered glomerular
permselectivity following glomerular antibody deposition.
Summary
Studies in the isolated perfused kidney have demonstrated
that, in addition to its role in activating complement and
recruiting other circulating mediators of injury, anti-GBM anti-
body can itself significantly alter renal hemodynamics. Anti-
body administration provoked an increased intrarenal renin
release, with a significant proportion of the antibody induced
hemodynamic change due to the enhanced intrarenal produc-
tion of angiotensin II. This study demonstrates the potential for
a direct intrarenal hemodynamic effect from the glomerular
fixation of antibody. Such direct antibody—induced injury may
contribute to the renal hemodynamic changes which occur in
antibody—associated experimental and human renal disease.
Reprint requests to Neil W. Boyce, M.D., Monash University De-
partment of Medicine, Prince Henry's Hospital, St. Kilda Road,
Melbourne, Victoria, Australia 3004.
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